Clinical Evaluation of Lamivudine in Combination with Interferon A for Chronic Hepatitis B

Objective To observe the efficiency and safety of interferon-α2b(IFN-α2b)combined with Lamivudine for chronic hepatitis B.Methods Sixty-six patients with chronic hepatitis B were randomly divided into 2 groups.The observation group(n=33)was administered with in IFN-α2b combined with Lamivudine,whereas the control group(n=33)only with IFN-α2b.The period of treatment was 12 months.Results The serum alanine aminotransferase level decreased significantly both groups(P0.02)at the end of treatment and 12 months later.The disappearance rates of HBeAg were 41.47% in the observation group and 26.33% in the control group respectively(P0.1),and the clearance rates of HBV DNA were 69.70% in the observation group and 36.47% in the control group respectively(P0.01)12 months after stopping administering.Influenza-like symptoms were observed in 86.57% of the patients treated with IFN-α2b.There was no obvious difference in the rate of side effects in both groups.Conclusions The IFN-α2b or IFN-α2b combined with Lamivudine is efficient for patients with chronic hepatitis B.The HBV DNA clearance effect by combination treatment is better than IFN-α2b treatment alone.